Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid

Wang, Qijun; Ruan, Yue; Guo, Fei; Zhu, Haiqin; Pan, Meng

doi:10.2340/actadv.v103.12324

Acta Derm Venereol

2023

DOI: 10.2340/actadv.v103.12324

|View full text |Cite

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid

Qijun Wang,

Yue Ruan,

Fei Guo

et al.

Abstract: is missing (Short communication)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Methotrexate/prednisone

2023

Reactions Weekly

View full text Add to dashboard Cite

Methotrexate/prednisone

2023

Reactions Weekly

View full text Add to dashboard Cite

Dupilumab-Associated Bilateral Conjunctival Papillomas and Corneal Perforation

Dewhurst,

Larney,

Jobson

et al. 2024

Cornea

View full text Add to dashboard Cite

Purpose: We report a unique case of significant human papillomavirus–associated conjunctival papillomas and severe corneal ulceration leading to corneal perforation in a patient treated with dupilumab for atopic dermatitis. Methods: This study is a case report and literature review of severe corneal side effects related to dupilumab. Results: A 27-year-old man with severe atopic dermatitis and no ocular history was administered dupilumab 300 mg via subcutaneous injections every 2 weeks with an excellent response. Following the onset of treatment, the patient developed conjunctivitis, conjunctival papillomas, and dry eyes, which were initially treated with lubricating eye drops. Fourteen months after commencing dupilumab, he had a rapid onset of painful visual loss in the OD accompanied by severe bilateral conjunctival injection and was found to have a central corneal ulcer and diffuse papillomas on the palpebral and bulbar conjunctiva. Despite management with intravenous methylprednisolone and topical dexamethasone, the patient's corneal ulcer progressed to a corneal melt, resulting in perforation 2 months after diagnosis, which necessitated a corneal graft. Conclusions: We present the third reported case of dupilumab-associated corneal perforation and the first case to our knowledge of dupilumab-associated conjunctival papillomas. As dupilumab usage increases, awareness of these potential complications among prescribers is essential.

show abstract

Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review

Granados-Betancort,

Sánchez-Díaz,

Muñoz-Barba

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Bullous pemphigoid (BP) is an autoimmune disease characterized by the appearance of very pruritic subepidermal blisters. It appears mostly in the elderly and is associated with multiple comorbidities, which makes its management and treatment difficult. The purpose of this systematic review is to compile current information on published cases of BP treated with omalizumab (omalizumab) and dupilumab (dupilumab) in order to obtain information on clinical efficacy and safety data available. Methods: A literature search of all cases of BP treated with omalizumab/dupilumab published in the literature up to January 2024 was performed using the Pubmed database. After an exhaustive search, a total of 61 studies encompassing 886 patients met the inclusion criteria and were included in the review. Results: The majority of patients with BP treated with omalizumab/dupilumab presented a significant improvement in symptomatology, being very safe drugs with minimal side effects. The main limitation of the presented review is the quality of the included studies, most of them being case series or individual cases. The development of studies with a higher level of scientific evidence in the near future would be of great interest. Conclusions: Both omalizumab and dupilumab appear to be effective options for treating BP in patients refractory to other pharmacological therapies. They are drugs with a good safety profile and the adverse reactions associated with their use are infrequent and generally mild.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid

Abstract: is missing (Short communication)

Cited by 3 publications

References 10 publications

Methotrexate/prednisone

Methotrexate/prednisone

Dupilumab-Associated Bilateral Conjunctival Papillomas and Corneal Perforation

Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review

Contact Info

Product

Resources

About